Sanofi $SNY Holdings Raised by Compound Planning Inc.

Key Points

• Compound Planning Inc. increased its stake in Sanofi by 37.2%, owning a total of 23,011 shares valued at approximately $1.276 million.
• Several institutional investors have also made moves in Sanofi, with significant increases in stakes from firms like Golden State Wealth Management LLC and Eastern Bank.
• Sanofi reported a missed earnings estimate of $0.90 EPS compared to the expected $0.96, although revenue exceeded expectations at $11.34 billion, despite a 7.0% year-over-year decline.

Compound Planning Inc. raised its holdings in Sanofi (NASDAQ:SNY - Free Report) by 37.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,011 shares of the company's stock after buying an additional 6,244 shares during the quarter. Compound Planning Inc.'s holdings in Sanofi were worth $1,276,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Accent Capital Management LLC acquired a new position in shares of Sanofi in the 1st quarter valued at about $29,000. Eastern Bank lifted its stake in shares of Sanofi by 121.0% in the 1st quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after purchasing an additional 300 shares in the last quarter. Golden State Wealth Management LLC lifted its stake in shares of Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after purchasing an additional 545 shares in the last quarter. Brentview Investment Management LLC acquired a new position in shares of Sanofi in the 1st quarter valued at about $42,000. Finally, UMB Bank n.a. lifted its stake in shares of Sanofi by 30.7% in the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after purchasing an additional 264 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Performance

SNY stock traded down $0.27 during trading on Friday, reaching $49.68. 764,216 shares of the company's stock were exchanged, compared to its average volume of 2,529,461. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. Sanofi has a 1-year low of $44.73 and a 1-year high of $60.12. The company's fifty day moving average price is $48.77 and its 200-day moving average price is $51.64. The firm has a market cap of $121.98 billion, a PE ratio of 11.94, a P/E/G ratio of 1.19 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same quarter last year, the firm posted $1.73 EPS. The company's revenue was down 7.0% compared to the same quarter last year. On average, research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on SNY shares. JPMorgan Chase & Co. raised Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Morgan Stanley set a $56.00 price objective on Sanofi in a research note on Monday, June 2nd. Barclays reiterated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Guggenheim reiterated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Sanofi in a report on Tuesday, August 5th. Three investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $62.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.